Alzheimer disease (AD) is the most common form of dementia which eventually leads to death. It was first described by (and later named after) the German psychiatrist and neuropathologist Alois Alzheimer in 1906. Most often, AD is diagnosed in people over 65 years of age, although the less-prevalent early-onset Alzheimer can occur in much younger people. In 2006, there were 26.6 million people worldwide with AD; by 2050 Alzheimer is predicted to affect 1 in 85 individuals globally.
Alzheimer is a debilitating disease not only for the person it has struck but also the people around him or her. I am bringing to my readers’ attention the company Neuronix in order to allow people to be equipped with the information and the understanding that there is something that could be done for sick one, their family members and even their friends, all of whom he or she being sick with the Alzheimer disease affects, in one way or another.
I first met the Neuronix team a year ago and recently we met again at The Israel Conference (http://theisraelconference.org/) in Los Angeles.
The Neuronix system is a combination of electronic pulses, concurrent with cognitive exercise that treats specific brain region affected by the Alzheimer disease. The system is directed especially at exercising duel stimulation that effects, in a long run, the way the brain works and the cognitive capability of the patient.
Neuronix system was invented by an Israeli neuropsychologist. At this stage it has already passed several successful medical trials in Israel and Harvard University. In following the system’s one hour each day, five days a week for six weeks intervention, the trials have shown remarkable improvements in the patient’s condition and state.
Neuronix offers treatment that can deal, as a huge break, with the Alzheimer disease. It is no cure but it causes the patient to improve his or her condition; they remember more, recognize family members better and their life quality is improved.
Neuronix has opened multiple study center, for FDA approval, in Boston, New York, Miami in Florida, Cleveland, Las Vegas, Sun City in Arizona and Costa Mesa in California. The study will go on till May 15, 2015 to be followed by the FDA approval.
If you know of someone who is suffering from the Alzheimer disease and has nothing to lose and all to gain, refer them or contact Neuronix and he or she may gain a better quality of life, while reducing the suffering and postponing the dreadful deterioration this disease causes.